Alivus Life Sciences Ltd
₹1,046.25+0.00%Apr 13, 3:45 PM IST
ALIVUS•Health Technology•Pharmaceuticals: Major
Current Price
₹1,046.25+0.00%
Apr 13, 3:45 PM ISTMarket Cap₹12,803.86 Cr
Market Cap₹12,803.86 Cr
Business Overview
Glenmark Life Sciences Limited operates through 2 main business divisions including Active Pharmaceutical Ingredients (APIs), Contract Development and Manufacturing Organization (CDMO).
Business Hierarchy Structure for Glenmark Life Sciences Limited
- Glenmark Life Sciences Limited
- Active Pharmaceutical Ingredients (APIs)
- Therapy Areas
- Cardiovascular (CVS) Disease
- Anti-hypertensives
- Olmesartan
- Telmisartan
- Perindopril
- Anti-hyperlipidemic
- Rosuvastatin
- Anti-arrhythmics
- Anti-coagulants
- Anti-hypertensives
- Oncology
- Belumosudil
- Daprodustat
- Elacestrant
- Finerenone
- Fezolinetant
- Tivozanib
- Vonoprazan
- Isavuconazonium Sulfate
- Central Nervous System (CNS) Disorders
- Zonisamide
- Diabetes
- Sitagliptin
- Pain Management
- Anti-migraine
- Analgesic
- Urology
- Mirabegron
- Anti-acne
- Anti-fungal
- Anti-histaminic
- Anti-emetic
- Anti-ulcerative
- Anti-viral
- Respiratory agents
- Ophthalmologic agent
- Cardiovascular (CVS) Disease
- Other APIs
- Atovaquone (anti-parasitic)
- Adapalene (dermatology)
- New Products under Development Pipeline
- Iron Complexes (3)
- Oncology Products (11)
- Therapy Areas
- Contract Development and Manufacturing Organization (CDMO)
- Active Pharmaceutical Ingredients (APIs)